JP7097373B2 - キナーゼ阻害剤としてのアミノトリアゾロピリジン - Google Patents

キナーゼ阻害剤としてのアミノトリアゾロピリジン Download PDF

Info

Publication number
JP7097373B2
JP7097373B2 JP2019543377A JP2019543377A JP7097373B2 JP 7097373 B2 JP7097373 B2 JP 7097373B2 JP 2019543377 A JP2019543377 A JP 2019543377A JP 2019543377 A JP2019543377 A JP 2019543377A JP 7097373 B2 JP7097373 B2 JP 7097373B2
Authority
JP
Japan
Prior art keywords
triazolo
amino
pyridine
pyridin
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019543377A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020507582A5 (enExample
JP2020507582A (ja
Inventor
ジュンチン・グオ
エイミー・シー・ハート
ジョン・イー・マコー
マイケル・イー・マーツマン
ウィリアム・ジェイ・ピッツ
スティーブン・エイチ・スパーゲル
スコット・ハンター・ワターソン
ムルガイア・アンダッパン・ムルガイア・スッバイア
チェン・ジエ
キャロリン・ダイアン・ジアーバ
グアンリン・ルオ
ジャンリアン・シ
シン－ユエン・シット
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2020507582A publication Critical patent/JP2020507582A/ja
Publication of JP2020507582A5 publication Critical patent/JP2020507582A5/ja
Application granted granted Critical
Publication of JP7097373B2 publication Critical patent/JP7097373B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2019543377A 2017-02-13 2018-02-12 キナーゼ阻害剤としてのアミノトリアゾロピリジン Active JP7097373B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762458144P 2017-02-13 2017-02-13
US62/458,144 2017-02-13
PCT/US2018/017755 WO2018148626A1 (en) 2017-02-13 2018-02-12 Aminotriazolopyridines as kinase inhibitors

Publications (3)

Publication Number Publication Date
JP2020507582A JP2020507582A (ja) 2020-03-12
JP2020507582A5 JP2020507582A5 (enExample) 2021-03-18
JP7097373B2 true JP7097373B2 (ja) 2022-07-07

Family

ID=61283335

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019543377A Active JP7097373B2 (ja) 2017-02-13 2018-02-12 キナーゼ阻害剤としてのアミノトリアゾロピリジン

Country Status (25)

Country Link
US (3) US10913738B2 (enExample)
EP (1) EP3580220B1 (enExample)
JP (1) JP7097373B2 (enExample)
KR (1) KR102549952B1 (enExample)
CN (1) CN110520423B (enExample)
AU (1) AU2018217488B2 (enExample)
BR (1) BR112019016635A2 (enExample)
CA (1) CA3053484A1 (enExample)
CY (1) CY1124978T1 (enExample)
DK (1) DK3580220T3 (enExample)
EA (1) EA039808B1 (enExample)
ES (1) ES2902676T3 (enExample)
HR (1) HRP20212000T1 (enExample)
HU (1) HUE057801T2 (enExample)
IL (1) IL268614B (enExample)
LT (1) LT3580220T (enExample)
MA (1) MA47460A (enExample)
MX (1) MX378515B (enExample)
PL (1) PL3580220T3 (enExample)
PT (1) PT3580220T (enExample)
RS (1) RS62801B1 (enExample)
SG (1) SG11201907335UA (enExample)
SI (1) SI3580220T1 (enExample)
SM (1) SMT202200001T1 (enExample)
WO (1) WO2018148626A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3580220B1 (en) * 2017-02-13 2021-11-17 Bristol-Myers Squibb Company Aminotriazolopyridines as kinase inhibitors
KR102662197B1 (ko) * 2017-10-30 2024-04-29 브리스톨-마이어스 스큅 컴퍼니 키나제 억제제로서의 아미노이미다조피리다진
JP7307734B2 (ja) 2018-01-26 2023-07-12 ブリストル－マイヤーズ スクイブ カンパニー キナーゼ阻害剤としてのアミノピロロトリアジン
AU2019301628C1 (en) 2018-07-09 2025-02-06 Lieber Institute, Inc. Pyridine carboxamide compounds for inhibiting NaV1.8
WO2020014243A1 (en) * 2018-07-09 2020-01-16 Lieber Institute, Inc. PYRIDAZINE COMPOUNDS FOR INHIBITING Nav1.8
CA3112519A1 (en) 2018-09-13 2020-03-19 Bristol-Myers Squibb Company Indazole carboxamides as kinase inhibitors
AU2019337612A1 (en) 2018-09-13 2021-05-13 Bristol-Myers Squibb Company 1H-indazole carboxamides as receptor-interacting protein kinase 1 inhibitors (RIPK1)
CN113166116B (zh) * 2019-01-25 2022-12-27 北京赛特明强医药科技有限公司 酰胺基桥连杂环类化合物、及其组合物与应用
US20220177462A1 (en) * 2019-03-22 2022-06-09 Genfleet Therapeutics (Shanghai) Inc. Substituted heterocyclic amide compound and preparation method therefor and pharmaceutical use thereof
JP7600228B2 (ja) 2019-10-03 2024-12-16 ブリストル－マイヤーズ スクイブ カンパニー キナーゼ阻害剤としてのインダゾールカルボキサミド
JP7441477B2 (ja) * 2020-02-13 2024-03-01 ▲勁▼方医▲薬▼科技（上海）有限公司 ジヒドロナフチリドン系化合物、その調製方法及び医薬への使用
CN114230565B (zh) * 2020-09-09 2023-10-27 成都奥睿药业有限公司 5-取代吲哚3-酰胺衍生物及其制备方法和用途
CN114262322B (zh) * 2020-09-16 2026-01-06 中国科学院上海有机化学研究所 一类细胞程序性坏死抑制剂及其制备方法和用途
AR123793A1 (es) * 2020-10-19 2023-01-11 Bristol Myers Squibb Co Compuestos de triazolopiridinilo como inhibidores de quinasas
TWI824626B (zh) * 2021-08-02 2023-12-01 大陸商勁方醫藥科技(上海)有限公司 Ripk1抑制劑的晶型及其酸式鹽和其酸式鹽的晶型
IL308349A (en) 2021-08-10 2024-01-01 Abbvie Inc NICOTINAMIDE RIPK1 INHIBITORS
TW202345852A (zh) 2022-03-16 2023-12-01 大陸商江蘇恆瑞醫藥股份有限公司 稠雜環類化合物、其製備方法及其在醫藥上的應用
CN114989079B (zh) * 2022-06-21 2023-06-23 中国药科大学 Ripk1激酶靶点抑制剂及其医药用途
AR131541A1 (es) 2023-01-07 2025-04-09 Syngenta Crop Protection Ag Compuestos de carboxamida novedosos
WO2025072395A1 (en) * 2023-09-27 2025-04-03 Bristol-Myers Squibb Company Triazolopyridinyl compounds as kinase inhibitors
WO2025109114A1 (en) 2023-11-24 2025-05-30 Syngenta Crop Protection Ag Novel carboxamide compounds
WO2025149637A1 (en) 2024-01-12 2025-07-17 Syngenta Crop Protection Ag Novel carboxamide compounds
WO2025149629A1 (en) 2024-01-12 2025-07-17 Syngenta Crop Protection Ag Novel carboxamide compounds
WO2026008750A1 (en) 2024-07-05 2026-01-08 Syngenta Crop Protection Ag Novel carboxamide compounds

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009532370A (ja) 2006-03-31 2009-09-10 アボット・ラボラトリーズ インダゾール化合物
WO2010007100A1 (en) 2008-07-15 2010-01-21 Cellzome Ltd 7-substituted amino triazoles as pi3k inhibitors
WO2016027253A1 (en) 2014-08-21 2016-02-25 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as rip1 kinase inhibitors as medicaments

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050288502A1 (en) * 2004-06-25 2005-12-29 Andersen Denise L Substituted heterocyclic compounds and methods of use
ES2320955B1 (es) * 2007-03-02 2010-03-16 Laboratorios Almirall S.A. Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida.
WO2009068482A1 (en) 2007-11-27 2009-06-04 Cellzome Limited Amino triazoles as pi3k inhibitors
WO2010057877A1 (en) 2008-11-18 2010-05-27 Cellzome Limited 7-pyridinyl- or phenyl- substituted triazolo [1, 5 -a] pyridines as pi3k inhibitors
US8598163B2 (en) 2009-02-04 2013-12-03 Vitae Pharmaceuticals, Inc. Derivatives of [1,3]Oxazin-2-one useful for the treatment of metabolic diseases such as lipid disorders
US9783573B2 (en) 2012-09-18 2017-10-10 Bristol-Myers Squibb Company IAP antagonists
TN2015000542A1 (en) 2013-06-10 2017-04-06 Bayer Pharma AG Novel compounds for the treatment of cancer
CN108349970B (zh) * 2015-11-05 2021-03-05 住友化学株式会社 稠合杂环化合物
WO2018017435A1 (en) 2016-07-22 2018-01-25 Accro Bioscience Inc. Heteroaryl compounds as inhibitors of necrosis, composition and application thereof
JP7190906B2 (ja) 2017-01-24 2022-12-16 住友化学株式会社 縮合複素環化合物及びそれを含有する組成物
EP3580220B1 (en) * 2017-02-13 2021-11-17 Bristol-Myers Squibb Company Aminotriazolopyridines as kinase inhibitors
KR102662197B1 (ko) 2017-10-30 2024-04-29 브리스톨-마이어스 스큅 컴퍼니 키나제 억제제로서의 아미노이미다조피리다진
JP7307734B2 (ja) 2018-01-26 2023-07-12 ブリストル－マイヤーズ スクイブ カンパニー キナーゼ阻害剤としてのアミノピロロトリアジン
AR123793A1 (es) * 2020-10-19 2023-01-11 Bristol Myers Squibb Co Compuestos de triazolopiridinilo como inhibidores de quinasas

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009532370A (ja) 2006-03-31 2009-09-10 アボット・ラボラトリーズ インダゾール化合物
WO2010007100A1 (en) 2008-07-15 2010-01-21 Cellzome Ltd 7-substituted amino triazoles as pi3k inhibitors
WO2016027253A1 (en) 2014-08-21 2016-02-25 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as rip1 kinase inhibitors as medicaments

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HARRIS, Philip A.，ACS Medicinal Chemistry Letters，2013年，4，1238-1243

Also Published As

Publication number Publication date
SMT202200001T1 (it) 2022-03-21
PL3580220T3 (pl) 2022-02-07
US10913738B2 (en) 2021-02-09
EA201991915A1 (ru) 2019-12-30
US12157733B2 (en) 2024-12-03
KR102549952B1 (ko) 2023-06-29
US20190389859A1 (en) 2019-12-26
SI3580220T1 (sl) 2022-01-31
CN110520423B (zh) 2022-08-23
IL268614B (en) 2021-12-01
AU2018217488A1 (en) 2019-10-03
EA039808B1 (ru) 2022-03-16
MX2019009555A (es) 2019-10-02
EP3580220B1 (en) 2021-11-17
WO2018148626A1 (en) 2018-08-16
ES2902676T3 (es) 2022-03-29
CA3053484A1 (en) 2018-08-16
US20220315580A1 (en) 2022-10-06
SG11201907335UA (en) 2019-09-27
HUE057801T2 (hu) 2022-06-28
BR112019016635A2 (pt) 2020-04-07
HRP20212000T1 (hr) 2022-04-01
AU2018217488B2 (en) 2021-09-23
MA47460A (fr) 2019-12-18
DK3580220T3 (da) 2022-01-10
KR20190117006A (ko) 2019-10-15
IL268614A (en) 2019-10-31
EP3580220A1 (en) 2019-12-18
JP2020507582A (ja) 2020-03-12
US20250074909A1 (en) 2025-03-06
PT3580220T (pt) 2022-01-03
CY1124978T1 (el) 2023-01-05
RS62801B1 (sr) 2022-02-28
LT3580220T (lt) 2021-12-27
MX378515B (es) 2025-03-11
CN110520423A (zh) 2019-11-29

Similar Documents

Publication Publication Date Title
JP7097373B2 (ja) キナーゼ阻害剤としてのアミノトリアゾロピリジン
JP7001682B2 (ja) 置換１Ｈ－イミダゾ［４，５－ｂ］ピリジン－２（３Ｈ）－オン及びＧＬＵＮ２Ｂ受容体調節因子としてのそれらの使用
US11618753B2 (en) Aminopyrrolotriazines as kinase inhibitors
EP3704118B1 (en) Aminoimidazopyridazines as kinase inhibitors
JP6215338B2 (ja) キナーゼモジュレーターとして有用な二環式ヘテロ環置換ピリジル化合物
CN104159896A (zh) 用作激酶抑制剂的杂环取代的吡啶基化合物
CN104254533A (zh) 用作激酶抑制剂的噻唑或噻二唑取代的吡啶基化合物
KR102906523B1 (ko) 수용체-상호작용 단백질 키나제 1 (ripk1) 억제제로서의 1h-인다졸 카르복스아미드
EA042124B1 (ru) Аминоимидазопиридазины в качестве ингибиторов киназ
NZ793902A (en) Substituted 2-azabicycles and their use as orexin receptor modulators
EA042342B1 (ru) Аминопирролотриазины в качестве ингибиторов киназы

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210202

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210202

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211202

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220202

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220607

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220627

R150 Certificate of patent or registration of utility model

Ref document number: 7097373

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250